Nanobody designWe computationally optimize small antibody fragments (VHH or nanobodies) capable of recognizing chosen epitopes with the aim of tailoring novel binders for medical and pharmaceutical applications. Evolved VHHs are then produced and analyzed for their affinity and stability in an iterative two-way transfer between empiric data and theoretical modeling [a,b]. We further study their humanization with the final aim of developing new anticancer drugs. Up to date our main achievement is the development of a computational protocol capable generating VHHs with nanomolar binding affinity towards a chosen epitope of a protein target [c]. We carry out this activity thanks to computational projects granted by CINECA (the Italian supercomputing centre for scientific research) and PRACE (Partnership for Advanced Computing in Europe), and funding from the European Social Fund, the Regional Operative Programme, Alternatives Research & Development Foundation (ARDF), and the Italian Association for Cancer Research (AIRC).
Current collaborators: |
Molecular Modeling for Medicinal ChemistryWe support medical doctors (and a collaborating network that includes the group of J.E. Rothman, 2013 Nobel Prize in Medicine) in modeling protein mutants [a,b], and synthetic medicinal chemists in modeling potential drugs [c] for a variety of systems of medical interest.
Current collaborators: |
New architectures for biosensing
Current collaborators: |
Molecular and colloidal self-assembly
Current collaborators: |